Five things for pharma marketers to know: Tuesday, August 23, 2016



1. Mylan is under fire over price increases for its emergency allergic reaction treatment, EpiPen. Sen, Charles Grassley (R-Iowa) wrote in a letter to Mylan CEO Heather Bresch that since the drugmaker acquired EpiPen from Merck KGaA in 2007, the cost has risen more than 400%  and “the substantial price increase could limit access to a much-needed medication.” (Grassley's letter)

2. Boehringer Ingelheim's Pradaxa continues to be the only modern anticoagulant with an FDA-approved reversal agent. The agency sent Portola Pharmaceuticals a complete response letter, requesting additional information about its investigational antidote designed to reverse the anticoagulating effects of Johnson & Johnson's Xarelto, Bristol-Myers Squibb's Eliquis, and Daiichi Sankyo's Savaysa. (FiercePharma)

3. The FDA approved Pfizer's abuse-deterrent opioid Troxyca ER. The drug is designed to deter abuse when crushed and then taken orally or snorted.

4. A new analysis of Medicaid data found no significant link between the use of antipsychotic drugs during pregnancy and an increased risk of congenital malformation defects. While overall use was not linked to significant risk, some drugs were associated with a higher risk of malformations. The study was conducted by researchers at Brigham and Women's Hospital in Boston. (MedPage Today)

5. Cinven, a private equity firm, said it will acquire clinical-trial services provider Bioclinica from Water Street Healthcare Partners and JLL Partners. Unnamed sources told The Wall Street Journal that Bioclinica was sold for $1.4 billion. (WSJ)